• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1274868 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type* A' W! m4 @% k) J0 u+ s* v
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
7 S- B% w% F) _& {% M+ Author Affiliations: H2 b% \# q1 M. k, _$ A4 ?3 m

* f+ [8 }: n/ j1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 B6 V$ [0 J. S3 a0 D( ^2 x: M2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ! b+ o! A. Q- H
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ F- x/ J5 d  \( D1 B+ k% J4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
$ n% m# g7 f2 O! A5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
5 B" @, ^- [) F( T; U. C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 s; x$ j, F! g0 }" [2 n$ B7Kinki University School of Medicine, Osaka 589-8511, Japan
! s8 S& ]  M1 ^9 \: p( M8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 `0 ~5 K' A' i3 f9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 9 L: R/ `' Z* v2 ~. ^6 [
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! o3 Q, M4 F  r! {+ J9 p+ U. `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 z; S6 @. |" H8 g3 }9 v9 P6 |# c+ E+ `' b3 {
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
2 u' b& _9 l; R; u4 x9 X" ^( ^3 l7 ^$ w% P
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
, t" ?* ~3 c5 z5 U* g4 i% r% \/ @' p7 Z9 _% l* M" O" F
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  * p) r) c! e1 c
0 B  m! _" N6 `( _
Published online on: Thursday, December 1, 2011 8 V( p. z, N5 t0 h& P0 N: Q7 ~8 u

4 `$ c: a- t4 y: s; K3 t0 J9 EDoi: 10.3892/ol.2011.507 7 `+ d& t7 P6 k

) n* w# `2 O4 B' x; @3 t1 _& h  NPages: 405-410 : }  e5 x" z- `

% f% i$ M. K9 t: fAbstract:) x! \( K  ?0 ^' j
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
9 z4 q7 h5 q+ c  |
# ~5 q1 P5 M7 K8 q* x7 z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population1 G( ]) I+ t, ~0 Y* ]- |0 L' h
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
$ W) F, A" `) C& t  S8 r& ^+ Author Affiliations
" F- R1 K/ R0 ^9 i1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
; d+ ~. H" U* M+ Q3 s2 X2Department of Thoracic Surgery, Kyoto University, Kyoto ' e5 X! B1 J3 W6 j: X. p, M
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
8 M8 D3 l+ p+ m1 T  A. O) S' j9 E&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp % f5 u; y+ j- V2 M. l
Received September 3, 2010.
$ L$ M5 n; P3 n) B; L' M9 K, SRevision received November 11, 2010.
% T# ?5 b3 l( g0 VAccepted November 17, 2010.
  e: z! K2 o% f( @4 tAbstract
- J: H2 v$ p) U+ y5 ABackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
1 m/ h- J0 I  }# I* M2 bPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ) Y# T9 S4 ^* r) ^) f9 ^
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
. b" V: Y: H) Y0 y: nConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
! W* [: s) n* R8 R7 O+ m
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。' M( U1 {0 b; H" N/ [" _
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?' w4 b/ U2 G1 y) [; I8 _# k" `
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy& q; M4 H- o+ e- n% {1 ~' X
http://clinicaltrials.gov/ct2/show/NCT01523587
: U5 w9 _6 W& @, d/ L6 P
) \, Z' I% x$ V" M/ }- n$ _6 DBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
" N' _" K+ ]% chttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
9 G: E' H/ G* g5 G+ ?# e$ b5 l; }, Y. V
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
- Y4 k  u5 F* K8 M至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

+ b8 d+ O, ]; a# Y& G  M没有副作用是第一追求,效果显著是第二追求。! B& ?4 `+ v" F$ g. A- D: A8 T- F' {
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表